Topical ranibizumab as a treatment of corneal neovascularization

Giulio Ferrari, Mohammad H. Dastjerdi, Andre Okanobo, Sheng Fu Cheng, Francisco Amparo, Nambi Nallasamy, Reza Dana

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA. Results: Statistically significant decreases in neovascular area (55.3%, P<0.001), which lasted through 16 weeks, and VC (59%, P <0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.

Original languageEnglish
Pages (from-to)992-997
Number of pages6
JournalCornea
Volume32
Issue number7
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Corneal Neovascularization
Therapeutics
Intraocular Pressure
Cornea
Visual Acuity
Ear
Outcome Assessment (Health Care)
Ranibizumab

Keywords

  • Corneal neovascularization
  • Ranibizumab
  • VEGF

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ferrari, G., Dastjerdi, M. H., Okanobo, A., Cheng, S. F., Amparo, F., Nallasamy, N., & Dana, R. (2013). Topical ranibizumab as a treatment of corneal neovascularization. Cornea, 32(7), 992-997. https://doi.org/10.1097/ICO.0b013e3182775f8d

Topical ranibizumab as a treatment of corneal neovascularization. / Ferrari, Giulio; Dastjerdi, Mohammad H.; Okanobo, Andre; Cheng, Sheng Fu; Amparo, Francisco; Nallasamy, Nambi; Dana, Reza.

In: Cornea, Vol. 32, No. 7, 07.2013, p. 992-997.

Research output: Contribution to journalArticle

Ferrari, G, Dastjerdi, MH, Okanobo, A, Cheng, SF, Amparo, F, Nallasamy, N & Dana, R 2013, 'Topical ranibizumab as a treatment of corneal neovascularization', Cornea, vol. 32, no. 7, pp. 992-997. https://doi.org/10.1097/ICO.0b013e3182775f8d
Ferrari G, Dastjerdi MH, Okanobo A, Cheng SF, Amparo F, Nallasamy N et al. Topical ranibizumab as a treatment of corneal neovascularization. Cornea. 2013 Jul;32(7):992-997. https://doi.org/10.1097/ICO.0b013e3182775f8d
Ferrari, Giulio ; Dastjerdi, Mohammad H. ; Okanobo, Andre ; Cheng, Sheng Fu ; Amparo, Francisco ; Nallasamy, Nambi ; Dana, Reza. / Topical ranibizumab as a treatment of corneal neovascularization. In: Cornea. 2013 ; Vol. 32, No. 7. pp. 992-997.
@article{bc7d4b84750a406ba87aa80e7130407a,
title = "Topical ranibizumab as a treatment of corneal neovascularization",
abstract = "Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1{\%}) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA. Results: Statistically significant decreases in neovascular area (55.3{\%}, P<0.001), which lasted through 16 weeks, and VC (59{\%}, P <0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3{\%}, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.",
keywords = "Corneal neovascularization, Ranibizumab, VEGF",
author = "Giulio Ferrari and Dastjerdi, {Mohammad H.} and Andre Okanobo and Cheng, {Sheng Fu} and Francisco Amparo and Nambi Nallasamy and Reza Dana",
year = "2013",
month = "7",
doi = "10.1097/ICO.0b013e3182775f8d",
language = "English",
volume = "32",
pages = "992--997",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Topical ranibizumab as a treatment of corneal neovascularization

AU - Ferrari, Giulio

AU - Dastjerdi, Mohammad H.

AU - Okanobo, Andre

AU - Cheng, Sheng Fu

AU - Amparo, Francisco

AU - Nallasamy, Nambi

AU - Dana, Reza

PY - 2013/7

Y1 - 2013/7

N2 - Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA. Results: Statistically significant decreases in neovascular area (55.3%, P<0.001), which lasted through 16 weeks, and VC (59%, P <0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.

AB - Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA. Results: Statistically significant decreases in neovascular area (55.3%, P<0.001), which lasted through 16 weeks, and VC (59%, P <0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.

KW - Corneal neovascularization

KW - Ranibizumab

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84879089061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879089061&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e3182775f8d

DO - 10.1097/ICO.0b013e3182775f8d

M3 - Article

C2 - 23407316

AN - SCOPUS:84879089061

VL - 32

SP - 992

EP - 997

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 7

ER -